COVID-19 Nucleocapsid Antibody COVIDNCAB

Synonyms

Allscripts (AEHR) Order Name

COVID-19 Nucleocapsid Antibody

Sunrise Clinical Manager (SCM) Order Name

COVID-19 Nucleocapsid Antibody

EPIC Order Name

COVID-19 Antibody (Nucleocapsid)

Clinical Info

This test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS‑CoV‑2, indicating recent or prior infection.

Specimen Type

Blood

Container

Gold or Lithium Heparin (Mint-green) top tube

Collection Instructions

Specimen: 1.0 mL serum or plasma (0.5 mL min)

Transport Instructions

Refrigerated

Specimen Stability

14 Days Room Temperature
14 Days Refrigerated
6 Months Frozen

Methodology

Electrochemiluminescence Immunoassay 

Days Performed

Sunday - Saturday
TAT: 2 Days

Performing Laboratory

Northwell Health Laboratories

CPT

86769

PDM

2153035

Result Interpretation

    Instrument       Methodology   Anti-SARS-CoV-2 Antibody Interpretation
Roche 801 (Elecsys Anti-SARS-CoV-2 ) Electrochemiluminescence immunoassay COI < 1.0 : Non-reactive for  anti-SARS-CoV-2 antibodies
COI ≥ 1.0 : Reactive for anti-SARS-CoV-2 antibodies

The Roche Elecsys Anti‑SARS‑CoV‑2 nucleocapsid assay has been approved by the FDA for Emergency Use Authorization only. It has been validated to be accurate by Northwell Health Laboratories.

Positive results indicate that antibodies against SARS-CoV-2 were detected in your blood. Presence of antibodies to SARS‑CoV‑2 may not guarantee protection from SARS-CoV-2 reinfection.

Negative results do not preclude SARS‑CoV‑2 infection and should not be used as the sole basis for patient management decisions. A negative result can occur if the quantity of the anti‑SARS‑CoV‑2 antibodies is below the detection limits of the assay, or the antibodies that are detected are not present during the stage of disease in which a sample is collected. Follow-up testing with a molecular diagnostic tets should be considered to rule out infection in these individuals

 

Forms

edit